🚀 VC round data is live in beta, check it out!
Piramal Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Piramal Pharma and similar public comparables like Fagron, PharmaResearch, Sai Life Sciences, Jiuzhou Pharmaceutical and more.
Piramal Pharma Overview
About Piramal Pharma
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
Founded
2020
HQ
Employees
7.1K
Website
Financials (LTM)
EV
$3B
Piramal Pharma Financials
Piramal Pharma reported last 12-month revenue of $961M and EBITDA of $104M.
In the same LTM period, Piramal Pharma generated $623M in gross profit, $104M in EBITDA, and had net loss of ($12M).
Revenue (LTM)
Piramal Pharma P&L
In the most recent fiscal year, Piramal Pharma reported revenue of $1B and EBITDA of $177M.
Piramal Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $961M | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $623M | XXX | $590M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $104M | XXX | $177M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | ($12M) | XXX | $11M | XXX | XXX | XXX |
| Net Margin | (1%) | XXX | 1% | XXX | XXX | XXX |
| Net Debt | — | — | $468M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Piramal Pharma Stock Performance
Piramal Pharma has current market cap of $2B, and enterprise value of $3B.
Market Cap Evolution
Piramal Pharma's stock price is $1.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $2B | 1.4% | XXX | XXX | XXX | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPiramal Pharma Valuation Multiples
Piramal Pharma trades at 2.7x EV/Revenue multiple, and 24.5x EV/EBITDA.
EV / Revenue (LTM)
Piramal Pharma Financial Valuation Multiples
As of April 18, 2026, Piramal Pharma has market cap of $2B and EV of $3B.
Equity research analysts estimate Piramal Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Piramal Pharma has a P/E ratio of (172.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 24.5x | XXX | 14.4x | XXX | XXX | XXX |
| EV/EBIT | 161.9x | XXX | 32.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | 4.3x | XXX | XXX | XXX |
| P/E | (172.4x) | XXX | 199.1x | XXX | XXX | XXX |
| EV/FCF | 49.9x | XXX | 104.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Piramal Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Piramal Pharma Margins & Growth Rates
Piramal Pharma's revenue in the last 12 month grew by 15%.
Piramal Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Piramal Pharma's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Piramal Pharma's rule of X is 41% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Piramal Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | (11%) | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 58% | XXX | (43%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Piramal Pharma Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fagron | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaResearch | XXX | XXX | XXX | XXX | XXX | XXX |
| Sai Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiuzhou Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Piramal Pharma M&A Activity
Piramal Pharma acquired XXX companies to date.
Last acquisition by Piramal Pharma was on XXXXXXXX, XXXXX. Piramal Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Piramal Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPiramal Pharma Investment Activity
Piramal Pharma invested in XXX companies to date.
Piramal Pharma made its latest investment on XXXXXXXX, XXXXX. Piramal Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Piramal Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Piramal Pharma
| When was Piramal Pharma founded? | Piramal Pharma was founded in 2020. |
| Where is Piramal Pharma headquartered? | Piramal Pharma is headquartered in India. |
| How many employees does Piramal Pharma have? | As of today, Piramal Pharma has over 7K employees. |
| Who is the CEO of Piramal Pharma? | Piramal Pharma's CEO is Peter DeYoung. |
| Is Piramal Pharma publicly listed? | Yes, Piramal Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Piramal Pharma? | Piramal Pharma trades under PPLPHARMA ticker. |
| When did Piramal Pharma go public? | Piramal Pharma went public in 2022. |
| Who are competitors of Piramal Pharma? | Piramal Pharma main competitors are Fagron, PharmaResearch, Sai Life Sciences, Jiuzhou Pharmaceutical. |
| What is the current market cap of Piramal Pharma? | Piramal Pharma's current market cap is $2B. |
| What is the current revenue of Piramal Pharma? | Piramal Pharma's last 12 months revenue is $961M. |
| What is the current revenue growth of Piramal Pharma? | Piramal Pharma revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Piramal Pharma? | Current revenue multiple of Piramal Pharma is 2.7x. |
| Is Piramal Pharma profitable? | Yes, Piramal Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Piramal Pharma? | Piramal Pharma's last 12 months EBITDA is $104M. |
| What is Piramal Pharma's EBITDA margin? | Piramal Pharma's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of Piramal Pharma? | Current EBITDA multiple of Piramal Pharma is 24.5x. |
| What is the current FCF of Piramal Pharma? | Piramal Pharma's last 12 months FCF is $51M. |
| What is Piramal Pharma's FCF margin? | Piramal Pharma's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Piramal Pharma? | Current FCF multiple of Piramal Pharma is 49.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.